These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 2117478)
41. [Phase I clinical study of human leukocytic interferon II for injections]. Garin AM; Lichinitser MR; Kuznetsov VP; Tiuliandin SA; Rubtsov BI Ter Arkh; 1983; 55(8):137-41. PubMed ID: 6415838 [No Abstract] [Full Text] [Related]
42. [Phase I-II study of recombinant interferon gamma]. Adachi K; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Nakada H; Tada A; Yamazaki H; Mukaiyama T Gan To Kagaku Ryoho; 1985 Jun; 12(6):1331-8. PubMed ID: 2988459 [TBL] [Abstract][Full Text] [Related]
43. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy. Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513 [TBL] [Abstract][Full Text] [Related]
44. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Sterman DH; Recio A; Haas AR; Vachani A; Katz SI; Gillespie CT; Cheng G; Sun J; Moon E; Pereira L; Wang X; Heitjan DF; Litzky L; June CH; Vonderheide RH; Carroll RG; Albelda SM Mol Ther; 2010 Apr; 18(4):852-60. PubMed ID: 20068553 [TBL] [Abstract][Full Text] [Related]
46. Small cell lung carcinoma. A phase II evaluation of r-interferon-gamma. Newman HF; Bleehen NM; Galazka A; Scott E Cancer; 1987 Dec; 60(12):2938-40. PubMed ID: 2824019 [TBL] [Abstract][Full Text] [Related]
47. Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study. Kuebler JP; Goodman PJ; Brown TD; Crawford ED; Reitz CL; Knight WA; Kish JA Invest New Drugs; 1990 Aug; 8(3):307-9. PubMed ID: 2125585 [No Abstract] [Full Text] [Related]
48. Cutaneous toxicity after intradermal vaccination with Mycobacterium vaccae against lung cancer and malignant mesothelioma. Pandha HS; Mortimer P; Souberbeille B; McCoubrie P; O'Brien ME Br J Dermatol; 2001 Mar; 144(3):648-9. PubMed ID: 11260047 [No Abstract] [Full Text] [Related]
49. [Long-term results of the treatment of diffuse systemic scleroderma with interferon-gamma]. Blétry O; Laraki R; Cabane J; Francès C; Piette JC; Soubrier M; Wechsler B; de Gennes C; Valat C; Cosserat J Rev Med Interne; 1993; 14(10):978. PubMed ID: 8009071 [TBL] [Abstract][Full Text] [Related]
50. "So much for that" by Lionel Shriver. Commentary. Dresser R Acad Med; 2015 Aug; 90(8):1052-3. PubMed ID: 26218364 [No Abstract] [Full Text] [Related]
51. Maximum tolerated doses of preparations from different manufacturers. Sherwin SA J Clin Oncol; 1987 Nov; 5(11):1852-3. PubMed ID: 3119788 [No Abstract] [Full Text] [Related]
52. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Monnet I; Breau JL; Moro D; Lena H; Eymard JC; Ménard O; Vuillez JP; Chokri M; Romet-Lemonne JL; Lopez M Chest; 2002 Jun; 121(6):1921-7. PubMed ID: 12065358 [TBL] [Abstract][Full Text] [Related]
53. [Treatment of malignant mesothelioma using intrapleural gamma interferon]. Boutin C Bull Acad Natl Med; 1990 Mar; 174(3):421-6; discussion 427. PubMed ID: 2117478 [TBL] [Abstract][Full Text] [Related]
54. [Treatment of mesothelioma with interferon gamma and interleukin 2]. Boutin C; Viallat JR; Astoul P Rev Pneumol Clin; 1990; 46(5):211-5. PubMed ID: 2127468 [TBL] [Abstract][Full Text] [Related]
56. [Malignant mesothelioma: study of prognostic factors in a series of 188 cases]. Viallat JR; Boutin C; Rey F; Astoul P; Farisse P Arch Anat Cytol Pathol; 1993; 41(5-6):205-11. PubMed ID: 8135581 [TBL] [Abstract][Full Text] [Related]